These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

398 related articles for article (PubMed ID: 27290716)

  • 1. The Clinical Applications of Extended-Release Abuse-Deterrent Opioids.
    Vadivelu N; Schermer E; Kodumudi G; Berger JM
    CNS Drugs; 2016 Jul; 30(7):637-46. PubMed ID: 27290716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current and future development of extended-release, abuse-deterrent opioid formulations in the United States.
    Webster LR; Markman J; Cone EJ; Niebler G
    Postgrad Med; 2017 Jan; 129(1):102-110. PubMed ID: 27915497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of extended-release opioid analgesics for the treatment of chronic pain.
    Gudin JA
    J Pain Palliat Care Pharmacother; 2013 Mar; 27(1):49-61. PubMed ID: 23527669
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of prescription opioids with abuse-deterrent technology to address opioid abuse.
    Michna E; Kirson NY; Shei A; Birnbaum HG; Ben-Joseph R
    Curr Med Res Opin; 2014 Aug; 30(8):1589-98. PubMed ID: 24738694
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oxycodone extended release capsules for the treatment of chronic pain.
    Mercadante S
    Expert Rev Neurother; 2017 May; 17(5):427-431. PubMed ID: 28277802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Projecting the cost, utilization, and patient care impact of prescribing extended release non-abuse-deterrent opioids to chronic pain patients.
    Yenikomshian MA; White AG; Carson ME; Garrison LP; Oderda GM; Biskupiak JE; Hlavacek PR; Roland CL
    J Opioid Manag; 2017; 13(5):291-301. PubMed ID: 29199395
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of Abuse Deterrent Formulations of Opioids in Patients With Chronic Pain in the United States: A Cost-Effectiveness Model.
    Kumar VM; Agboola F; Synnott PG; Segel C; Webb M; Ollendorf DA; Banken R; Chapman RH
    Value Health; 2019 Apr; 22(4):416-422. PubMed ID: 30975392
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mitigation of IV Abuse Through the Use of Abuse-Deterrent Opioid Formulations: An Overview of Current Technologies.
    Rauck RL
    Pain Pract; 2019 Apr; 19(4):443-454. PubMed ID: 30597739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tamper-resistant opioid formulations in the treatment of acute pain.
    Passik SD
    Adv Ther; 2014 Mar; 31(3):264-75. PubMed ID: 24526323
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary care considerations of the pharmacokinetics and clinical use of extended-release opioids in treating patients with chronic noncancer pain.
    Nicholson B
    Postgrad Med; 2013 Jan; 125(1):115-27. PubMed ID: 23391677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Opioids with abuse-deterrent properties: A regulatory and technological overview.
    Haddox JD
    J Opioid Manag; 2017; 13(6):397-413. PubMed ID: 29308587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Will abuse-deterrent formulations of opioid analgesics be successful in achieving their purpose?
    Bannwarth B
    Drugs; 2012 Sep; 72(13):1713-23. PubMed ID: 22931520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Legal liability perspectives on abuse-deterrent opioids in the treatment of chronic pain.
    Brushwood DB; Rich BA; Coleman JJ; Bolen J; Wong W
    J Pain Palliat Care Pharmacother; 2010 Dec; 24(4):333-48. PubMed ID: 21133741
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic and pharmacodynamic evaluation of oxycodone and naltrexone for the treatment of chronic lower back pain.
    Davis MP
    Expert Opin Drug Metab Toxicol; 2016 Jul; 12(7):823-31. PubMed ID: 27253690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Routes of abuse of prescription opioid analgesics: a review and assessment of the potential impact of abuse-deterrent formulations.
    Gasior M; Bond M; Malamut R
    Postgrad Med; 2016 Jan; 128(1):85-96. PubMed ID: 26566680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term efficacy, safety and tolerability of Remoxy for the management of chronic pain.
    Pergolizzi JV; Zampogna G; Taylor R; Raffa RB
    Expert Rev Neurother; 2015 Mar; 15(3):231-8. PubMed ID: 25683255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Abuse-deterrent and tamper-resistant opioid formulations: what is their role in addressing prescription opioid abuse?
    Schneider JP; Matthews M; Jamison RN
    CNS Drugs; 2010 Oct; 24(10):805-10. PubMed ID: 20839893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abuse-deterrent and tamper-resistant opioids: how valuable are novel formulations in thwarting non-medical use?
    Lourenço LM; Matthews M; Jamison RN
    Expert Opin Drug Deliv; 2013 Feb; 10(2):229-40. PubMed ID: 23252692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use and abuse of opioid analgesics: potential methods to prevent and deter non-medical consumption of prescription opioids.
    Woolf CJ; Hashmi M
    Curr Opin Investig Drugs; 2004 Jan; 5(1):61-6. PubMed ID: 14983975
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Morphine sulfate abuse-deterrent formulations for the treatment of chronic pain.
    Fanelli A; Sorella MC; Ghisi D
    Expert Rev Clin Pharmacol; 2018 Dec; 11(12):1157-1162. PubMed ID: 30403896
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.